Gilead Sciences stock heads into Denver with new liver data
Published on 11/02/2026 at 16:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch next
- Gilead will present 21 abstracts at the Liver Meeting 2026 from November 5 to 9 in Denver.
- Phase 3 Livdelzi results and long-term Hepcludex data will put the liver pipeline in focus.
- The program offers a near-term pipeline catalyst beyond Gilead's established HIV franchise.
Gilead Sciences is heading into a key liver-disease conference with a broad research program. In a release dated October 22, the company said it would present 21 abstracts at The Liver Meeting 2026 in Denver from November 5 to 9. The Gilead release covers primary biliary cholangitis and chronic hepatitis delta.
Focus on Livdelzi and Hepcludex
The program includes late-breaking Phase 3 findings from the IDEAL study of Livdelzi, or seladelpar, in primary biliary cholangitis. Gilead is also scheduled to present long-term and real-world evidence for Hepcludex, or bulevirtide-gmod, in chronic hepatitis delta infection.
The Hepcludex program includes 96-week data on combined virologic and biochemical response. A separate analysis examines clinically significant portal hypertension after 48 weeks of treatment. For Livdelzi, the presentations address alkaline phosphatase normalization and treatment experience extending to five years.
Pipeline catalyst ahead of presentations
The findings could give investors a closer look at the durability of Gilead's liver portfolio and its potential contribution beyond HIV. The company has announced the agenda, but the detailed results will emerge during the presentations in Denver.
Stock moves above the prior report
The real-time quote of Gilead Sciences stock was 150.81 euros on Lang & Schwarz at 16:06 CET on Monday, November 2, 2026, 2.28 percent below the Xetra close of 154.32 euros on Friday, October 30, based on the Xetra quote shown by TradingView.
The October 29 report cited a Lang & Schwarz price of 144.36 euros. The current quote is therefore 4.47 percent higher than that prior report's reference, a separate comparison from the daily move against the October 30 Xetra close.
Gilead Sciences at a glance
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Home exchange: Nasdaq
- Lang & Schwarz price: 150.81 euros on November 2, 2026, at 16:06 CET
- Change versus Xetra close: 2.28 percent below 154.32 euros on October 30, 2026
- Upcoming event: The Liver Meeting 2026 in Denver, November 5 to 9
The US market backdrop can be followed through the S&P 500.
More research and market analysis is available on the Gilead Sciences stock topic page.
